{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:54Z","timestamp":1790996214094,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF\u03baB) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF\u03baB signaling and illustrated the ability of CD40L to activate the alternative NF\u03baB pathway in MCL. This activation leads to independency of classical NF\u03baB signaling and results in resistance to BCR inhibitors. Therefore, ligands (such as CD40L) and their activation of the alternative NF\u03baB pathway have a major impact on the drug response in MCL. Furthermore, this study indicates a protective role for cells expressing specific ligands as microenvironmental niches for MCL cells and underlines the significance of therapeutically targeting alternative NF\u03baB signaling in MCL.<\/jats:p>","DOI":"10.1038\/s41419-017-0157-6","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T14:58:30Z","timestamp":1516805910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CD40L mediated alternative NF\u03baB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Hilka","family":"Rauert-Wunderlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Berberich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"157_CR1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259","volume":"78","author":"M Raffeld","year":"1991","unstructured":"Raffeld, M. & Jaffe, E. S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78, 259\u2013263 (1991).","journal-title":"Blood"},{"key":"157_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/5.suppl_1.S71","volume":"5","author":"ME Williams","year":"1994","unstructured":"Williams, M. E. & Swerdlow, S. H. Cyclin D1 overexpression in non-Hodgkin\u2019s lymphoma with chromosome 11 bcl-1 rearrangement. Ann. Oncol. 5, 71\u201373 (1994).","journal-title":"Ann. Oncol."},{"key":"157_CR3","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416\u20133423 (2012).","journal-title":"J. Clin. Invest."},{"key":"157_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cpt.85","volume":"97","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Zhang, L. L., Champlin, R. E. & Wang, M. L. Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies. Clin. Pharmacol. Ther. 97, 455\u2013468 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"157_CR5","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075\u201313080 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"157_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MOH.0000000000000048","volume":"21","author":"M Buchner","year":"2014","unstructured":"Buchner, M. & Muschen, M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr. Opin. Hematol. 21, 341\u2013349 (2014).","journal-title":"Curr. Opin. Hematol."},{"key":"157_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron, D. et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 4, 1022\u20131035 (2014).","journal-title":"Cancer Discov."},{"key":"157_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Liu, C., Tsui, S. T. & Liu, D. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9, 80 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"157_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal, R. et al. Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma. Nat. Med. 20, 87\u201392 (2014).","journal-title":"Nat. Med."},{"key":"157_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2013.12.011","volume":"25","author":"D Colomer","year":"2014","unstructured":"Colomer, D. & Campo, E. Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. Cancer Cell 25, 7\u20139 (2014).","journal-title":"Cancer Cell"},{"key":"157_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen, F. et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 13, 45 (2015).","journal-title":"BMC Med."},{"key":"157_CR12","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604\u20134613 (2009).","journal-title":"Blood"},{"key":"157_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","volume":"21","author":"JA Burger","year":"2011","unstructured":"Burger, J. A. & Ford, R. J. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin. Cancer Biol. 21, 308\u2013312 (2011).","journal-title":"Semin. Cancer Biol."},{"key":"157_CR14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","volume":"1","author":"KD Jayappa","year":"2017","unstructured":"Jayappa, K. D. et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 1, 933\u2013946 (2017).","journal-title":"Blood Adv."},{"key":"157_CR15","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/sj.leu.2401829","volume":"14","author":"HP Visser","year":"2000","unstructured":"Visser, H. P., Tewis, M., Willemze, R. & Kluin-Nelemans, J. C. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia 14, 1483\u20131489 (2000).","journal-title":"Leukemia"},{"key":"157_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517\u2013534 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"157_CR17","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/sj.onc.1202568","volume":"17","author":"SJ Baker","year":"1998","unstructured":"Baker, S. J. & Reddy, E. P. Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261\u20133270 (1998).","journal-title":"Oncogene"},{"key":"157_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.20080238","volume":"205","author":"C H\u00f6mig-H\u00f6lzel","year":"2008","unstructured":"H\u00f6mig-H\u00f6lzel, C. et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J. Exp. Med. 205, 1317\u20131329 (2008).","journal-title":"J. Exp. Med."},{"key":"157_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"157_CR20","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron, D. et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget 6, 8750\u20138759 (2015).","journal-title":"Oncotarget"},{"key":"157_CR21","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1038\/sj.onc.1209934","volume":"25","author":"C Scheidereit","year":"2006","unstructured":"Scheidereit, C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25, 6685\u20136705 (2006).","journal-title":"Oncogene"},{"key":"157_CR22","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1038\/sj.onc.1209933","volume":"25","author":"A Hoffmann","year":"2006","unstructured":"Hoffmann, A., Natoli, G. & Ghosh, G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 25, 6706\u20136716 (2006).","journal-title":"Oncogene"},{"key":"157_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.it.2008.07.003","volume":"29","author":"SC Sun","year":"2008","unstructured":"Sun, S. C. & Ley, S. C. New insights into NF-kappaB regulation and function. Trends Immunol. 29, 469\u2013478 (2008).","journal-title":"Trends Immunol."},{"key":"157_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71\u201385 (2011).","journal-title":"Cell Res."},{"key":"157_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.13973","volume":"173","author":"H Rauert-Wunderlich","year":"2016","unstructured":"Rauert-Wunderlich, H., Rudelius, M., Ott, G. & Rosenwald, A. Targeting protein kinase C in mantle cell lymphoma. Br. J. Haematol. 173, 394\u2013403 (2016).","journal-title":"Br. J. Haematol."},{"key":"157_CR26","doi-asserted-by":"publisher","first-page":"e59292","DOI":"10.1371\/journal.pone.0059292","volume":"8","author":"H Rauert-Wunderlich","year":"2013","unstructured":"Rauert-Wunderlich, H. et al. The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFkappaB transcription factors. PLoS One 8, e59292 (2013).","journal-title":"PLoS One"},{"key":"157_CR27","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.1074\/jbc.M109.037341","volume":"285","author":"H Rauert","year":"2010","unstructured":"Rauert, H. et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 285, 7394\u20137404 (2010).","journal-title":"J. Biol. Chem."},{"key":"157_CR28","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron, D. et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood 128, 2808\u20132818 (2016).","journal-title":"Blood"},{"key":"157_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bcp.2006.08.007","volume":"72","author":"E Dejardin","year":"2006","unstructured":"Dejardin, E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72, 1161\u20131179 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"157_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fimmu.2013.00139","volume":"4","author":"T So","year":"2013","unstructured":"So, T. & Croft, M. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front. Immunol. 4, 139 (2013).","journal-title":"Front. Immunol."},{"key":"157_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"key":"157_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 31, 88\u201394 (2013).","journal-title":"J. Clin. Oncol."},{"key":"157_CR33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin, P. et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127, 1559\u20131563 (2016).","journal-title":"Blood"},{"key":"157_CR34","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao, G., Zhang, M., Harhaj, E. W. & Sun, S. C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279, 26243\u201326250 (2004).","journal-title":"J. Biol. Chem."},{"key":"157_CR35","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","volume":"97","author":"DJ Medina","year":"2012","unstructured":"Medina, D. J. et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica 97, 1255\u20131263 (2012).","journal-title":"Haematologica"},{"key":"157_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.leu.2401664","volume":"14","author":"R Castillo","year":"2000","unstructured":"Castillo, R. et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 14, 292\u2013298 (2000).","journal-title":"Leukemia"},{"key":"157_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1440-1711.2003.01171.x","volume":"81","author":"M Wykes","year":"2003","unstructured":"Wykes, M. Why do B cells produce CD40 ligand? Immunol. Cell Biol. 81, 328\u2013331 (2003).","journal-title":"Immunol. Cell Biol."},{"key":"157_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00125-006-0222-7","volume":"49","author":"F Angelico","year":"2006","unstructured":"Angelico, F. et al. Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 49, 1169\u20131174 (2006).","journal-title":"Diabetologia"},{"key":"157_CR39","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V96.6.2219","volume":"96","author":"NS Andersen","year":"2000","unstructured":"Andersen, N. S. et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 96, 2219\u20132225 (2000).","journal-title":"Blood"},{"key":"157_CR40","first-page":"691","volume":"24","author":"Z Jin","year":"2004","unstructured":"Jin, Z. et al. CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines. Anticancer Res. 24, 691\u2013697 (2004). (2B).","journal-title":"Anticancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0157-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:34:28Z","timestamp":1671536068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0157-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1038\/s41419-017-0157-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"18 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"86"}}